中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

难治性慢性丙型肝炎患者抗病毒治疗中NK细胞和Treg细胞的动态变化

陈晓云 张永宏 马丽娜 金怡 于海滨 郑艳红 刘宁 刘金花 王健 陈新月

引用本文:
Citation:

难治性慢性丙型肝炎患者抗病毒治疗中NK细胞和Treg细胞的动态变化

DOI: 10.3969/j.issn.1001-5256.2014.06.008
详细信息
  • 中图分类号: R512.63

Changes in NK cells and regulatory T cells among patients with refractory chronic hepatitis C during antiviral treatment

  • 摘要: 目的观察难治性慢性丙型肝炎的NK细胞和Treg细胞动态变化,分析与抗病毒疗效相关的免疫因素。方法采用开放性、前瞻性临床队列研究。入组2009年9月-2010年10月收治的难治性慢性丙型肝炎患者41例(初治组30例和无应答组11例)和健康对照(HC)者11例,初治组给予聚乙二醇干扰素(PEG-IFN)α-2a 180μg/周联合利巴韦林10.615 mg·kg-1·d-1治疗48周,无应答组给予PEG-IFNα-2a 180μg/周联合利巴韦林15 mg·kg-1·d-1治疗72周;动态留取细胞和血清,进行HCV RNA、肝功能和NK细胞和Treg细胞的检测,分析与疗效相关的免疫因素。计量资料采用t检验或秩和检验,计数资料采用χ2检验。结果所有患者均完成抗病毒治疗和24周随访,初治获得SVR者17例(56.7%),未获得SVR(nSVR)者13例;无应答组获得SVR者3例(27.2%),未获得SVR(RFP)者为8例(72.7%)。基线总体患者的NK细胞频率低于HC组,Treg细胞频率高于HC组;同时抗病毒治疗疗程中,初治获得SVR者24周NK细胞频率较基线和4周明...

     

  • [1] World Health Organization.Global surveillance and control of hepatitis C.Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium[J].J Viral Hepat, 1999, 6 (1) :35-47.
    [2] CHEN YS, LI L, CUI FQ, et al.A sero-epidemiological study on hepatitis C in China[J].Chin J Epidemiol, 2011, 32 (9) :888-891. (in Chinese) 陈园生, 李黎, 崔富强, 等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志, 2011, 32 (9) :888-891.
    [3]XIE Y, XU DZ, LU ZM, et al.The influence of HCV genotype on the IFN treatment of patients with chronic C[J].Chin J Hepatol, 2004, 12 (2) :72-75. (in Chinese) 谢尧, 徐道振, 陆志檬, 等.HCV基因型对慢性丙型肝炎干扰素疗效的影响[J].中华肝脏病杂志, 2004, 12 (2) :72-75.
    [4]XU B, LYU P, ZHU M.Epidemiological aspects of the genotype of hepatitis C virus[J].Chin J Exp Clin Virol, 2000, 14 (2) :148-150. (in Chinese) 徐蓓, 吕屏, 朱玫.慢性丙型肝炎患者HCV基因型调查[J].中华实验和临床病毒学杂志, 2000, 14 (2) :148-150.
    [5]YAN Y, LI Z, GUO XH, et al.A study on HCV-RNA quantitative detection and genotype in Peking[J].J Med Theory Pract, 2007, 20 (7) :756-757. (in Chinese) 严艳, 李卓, 郭向华, 等.北京地区慢性丙型肝炎患者血清HCV-RNA定量检测与基因分型的研究[J].医学理论与实践, 2007, 20 (7) :756-757.
    [6] HADZIYANNIS SJ, SETTE H JR, MORGAN TR, et al.Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.
    [7]AFDHAL NH.The natural history of hepatitis C[J].Semin Liver Dis, 2004, 24 (Suppl 2) :3-8.
    [8] GHANY MG, STRADER DB, THOMAS DL, et al.Diagnosis, management, and treatment of hepatitis C:an update[J].Hepatology, 2009, 49 (4) :1335-1374.
    [9]SHERMAN M, SHAFRAN S, BURAK K, et al.Management of chronic hepatitis C:consensus guidelines[J].Can J Gastroenterol, 2007, 21 (Suppl C) :25C-34C.
    [10]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology, Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].J Clin Hepatol, 2004, 20 (4) :197-203. (in Chinese) 中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].临床肝胆病杂志, 2004, 20 (4) :197-203.
    [11]SAKAGUCHI S, SAKAGUCHI N, ASANO M, et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25) .Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol, 1995, 155 (3) :1151-1164.
    [12] HORI S, NOMURA T, SAKAGUCHI S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science, 2003, 299 (5609) :1057-1061.
    [13] CALIGIURI M.Human nature killer cell[J].J Blood, 2008, 112 (3) :461-469.
    [14] POLI A, MICHEL T, THRESINE M, et al.CD56bright natural killer (NK) cells:An important NK cell subset[J].Immunology, 2009, 126 (4) :458-465.
    [15]MORETTA L, FERLAZZO G, BOTTINO C, et al.Effector and regulatory events during natural killer-dendritic cell interactions[J].Immunol Rev, 2006, 214 (1) :219-228.
    [16]DESSOUKI O, KAMIYA Y, NAGAHAMA H, et al.Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion:Reversion byanti-viral treatment[J].Biochem Biophys Res Commun, 2010, 393 (2) :331-337.
    [17]AMADEI B, URBANI S, CAZALY A, et al.Activation of natural killer cells during acute infection with hepatitis C virus[J].Gastroenterology, 2010, 138 (4) :1536-1545.
    [18]MORISHIMA C, PASCHAL DM, WANG CC, et al.Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing[J].Hepatology, 2006, 43 (3) :573-580.
    [19]LIN AW, GONZALEZ SA, CUNNINGHAM-RUNDLES S, et al.CD56 (+dim) and CD56 (+bright) cell activation and apoptosis in hepatitis C virus infection[J].Clin Exp Immunol, 2004, 137 (2) :408-416.
    [20] YOSHIZAWA K, ABE H, KUBO Y, et al.Expansion of CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells in hepatitis C virus-related chronic hepatitis, cirrhosis and hepatocellular carcinoma[J].Hepatol Res, 2010, 40 (2) :179-187.
    [21]BOLACCHI F, SINISTRO A, CIAPRINI C, et al.Increased hepatitis C virus (HCV) -specific CD4+CD25+regulatory T lymphocytes and reduced HCV-specific CD4+T cell response in HCVinfected patients with normal versus abnormal alanine aminotransferase levels[J].Clin Exp Immunol, 2006, 144 (2) :188-196.
    [22]TERME M, CHAPUT N, COMBADIERE B, et al.Regulatory T cells control dendritic cell/NK cell cross-talk in lymph nodes at the steady state by inhibiting CD4+self-reactive T cells[J].J Immunol, 2008, 180 (7) :4679-4686.
    [23]LEE S, WATSON MW, FLEXMAN JP, et al.Increased proportion of the CD56 (bright) NK cell subset in patients chronically infected with hepatitis C virus (HCV) receiving interferon-alpha and ribavirin therapy[J].J Med Virol, 2010, 82 (4) :568-574.
    [24]BURTON JR, KLARQUIST J, IM K, et al.Prospective analysis of effector and regulatory CD4+T cells in chronic HCV patients undergoing combination antiviral therapy[J].J Hepatol, 2008, 49 (3) :329-338.
    [25]LEE S, HAMMOND T, WATSON MW, et al.Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes frompatients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?[J].Clin Exp Immunol, 2010, 161 (1) :118-126.
    [26]SOLDEVILA B, ALONSO N, MARTíNEZ-ARCONADA MJ, et al.A prospective study of T-and B-lymphocyte subpopulations, CD81 expression levels on B cells and regulatory CD4 (+) CD25 (+) CD127 (low/-) FoxP3 (+) T cells in patients with chronic HCV infection during pegylated interferon-alpha 2a plus ribavirin treatment[J].J Viral Hepat, 2011, 18 (6) :384-392.
    [27]FRANCESCHINI D, PAROLI M, FRANCAVILLA V, et al.PDL1 negatively regulates CD4+CD25+Foxp3+Tregs by limiting STAT-5 phosphorylation in patients chronicallyinfected with HCV[J].J Clin Invest, 2009, 119 (3) :551-564.
    [28]AKIYAMA M, ICHIKAWA T, MIYAAKI H, et al.Relationship between regulatory T cells and the combination of pegylated interferon and ribavirin for the treatment of chronic hepatitis type C[J].Intervirology, 2010, 53 (3) :154-160.
    [29]TSENG KC, HO YC, HSIEH YH, et al.Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C[J].J Gastroenterol, 2012, 47 (7) :823-833.
  • 加载中
计量
  • 文章访问数:  3005
  • HTML全文浏览量:  15
  • PDF下载量:  654
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-08-20
  • 出版日期:  2014-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回